NOW APPROVED

for the treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as post-auto-HSCT consolidation.1

Full Prescribing Information

Full Prescribing Information

Request visit

Request visit from a representative (HCPs only)

ADCETRIS Patient Brochure

ADCETRIS Patient Brochure


Indication

ADCETRIS is indicated for use in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as consolidation treatment after an autologous hematopoietic stem cell transplantation.

Important Safety Information

BOXED WARNING

Progressive multifocal leukoencephalopathy (PML): A rare but serious infection of the brain that can lead to death and can occur in patients receiving ADCETRIS® (brentuximab vedotin).

What other therapies should I not be on with ADCETRIS?
You should not receive ADCETRIS if you are taking bleomycin because of possible side effects in the lungs.

Warnings and Precautions

Adverse Reactions:
ADCETRIS was studied in a trial with 329 patients with classical HL at high risk of relapse or progression after autologous hematopoietic stem cell transplantation. The most common side effects in patients who received ADCETRIS (167 patients) were a low number of white blood cells, tingling or numbness in the hands or feet, a low number of platelets (which help the blood clot), a low number of red blood cells, an infection in the upper respiratory tract, feeling tired, trouble moving the hands or feet, nausea, cough, and diarrhea.

Drug Interactions:
It is possible for ADCETRIS to interact with certain types of drugs. Make sure you tell your doctor everything you are taking.

Use in Specific Populations:
The amount of the drug part of ADCETRIS (MMAE) and side effects are higher in patients with moderate or severe liver or severe kidney disease. Use of ADCETRIS should be avoided in these patients.

Any suspected side effects should be reported to Seattle Genetics, Inc., at 855.473.2436 or the FDA at 800.FDA.1088 or www.fda.gov/medwatch.